The spectrum of liver disease among HIV-infected patients is changing. In the era of antiretroviral therapy, opportunistic infections are diminishing and deranged liver function appears to be due usually to drug-induced liver injury, alcohol, non-alcoholic steatohepatitis (NASH) or chronic hepatitis B. To test this hypothesis, 98 HIV-positive patients with deranged liver function were compared with matched HIV-positive patients with normal liver function and likewise matched HIV-negative patients with normal liver function tests.
BicaIMcGovernBDharR. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis2001; 32: 492–497.
2.
WeberRSabinCAFriis-MollerN. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med2006; 166: 1632–1641.
3.
GuptaSSinghS. Hepatitis B and C virus co-infections in human immunodeficiency virus positive North Indian patients. World J Gastroenterol2006; 12: 6879–6883.
4.
PolSLebrayPVallet-PichardA. HIV infection and hepatic enzyme abnormalities: intricacies of the pathogenic mechanisms. Clin Infect Dis2004; 38: S65–S72.
5.
BattegayM. Choice of initial therapy. J Int AIDS Soc2014; 17(Suppl. 3): 19488–19488.
6.
Mata-MarínJAGaytán-MartínezJGrados-ChavarríaBH. Correlation between HIV viral load and aminotransferases as liver damage markers in HIV infected naive patients: a concordance cross sectional study. Virol J2009; 6: 181–181.
7.
Crum-CianfloneNCollinsGMedinaS. Prevalence and factors associated with liver test abnormalities among human immunodeficiency virus-infected persons. Clin Gastroenterol Hepatol2010; 8: 183–191.
8.
VispoEMorenoAMaidaI. Noncirrhotic portal hypertension in HIV-infected patients: unique clinical and pathological findings. AIDS2010; 24: 1171–1176.
9.
OcamaPKatwereMPiloyaT. The spectrum of liver diseases in HIV infected individuals at an HIV treatment clinic in Kampala, Uganda. Afr Health Sci2008; 8: 8–12.
DayCP. Who gets alcoholic liver disease: nature or nurture? (extended abstract). Acta Gastroenterol Belg2003; 66: 290–291; discussion 292–293.
12.
ChalasaniNPHayashiPHBonkovskyHL. Practice Parameters Committee of the American College of Gastroenterology. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol2014; 109: 950–966.
13.
SPSS Inc. Released 2007. SPSS for Windows, Version 16.0. Chicago, IL: SPSS Inc.
14.
Ruppik M, Ledergerber B, Rickenbach M, et al. Changing patterns of causes of death: SHCS, 2005 to 2009. Paper presented at: 18th Conference on Retroviruses and Opportunistic Infections; February 27–March 2, 2011; Boston, MA.
15.
RameshKGandhiSRaoV. Clinical profile of human immunodeficiency virus patients with opportunistic infections: A descriptive case series study. Int J Appl Basic Med Res2015; 5: 119–123.
MugusiSNgaimisiEJanabiM. Liver enzyme abnormalities and associated risk factors in HIV patients on efavirenz-based HAART with or without tuberculosis co-infection in Tanzania. PLoS One2012; 7: e40180–e40180.
18.
BrunoRSacchiPFiliceG. Mitochondrial toxicity in HIV-HCV coinfection: It depends on the choice of antiretroviral drugs?Hepatology2002; 35: 500–501.
19.
PasupathiPBakthavathsalamGSaravananG. Changes in CD4 count, lipid profile and liver enzymes in HIV infection and AIDS patients. J Appl Biomed2008; 6: 139–145.
20.
Rogowska-SzadkowskaDBorzuchowskaA. The level of triglycerides, total cholesterol and HDL cholesterol in various stages of human immunodeficiency virus (HIV) infection. Pol Arch Med Wewn1999; 101: 145–150.
21.
National AIDS Control Organization (NACO) and Ministry of Health and Family Welfare. Natural History and Clinical Manifestation of HIV/AIDS. Specialist Training and Reference Module, New Delhi: Government of India, 2003.
22.
De SantisGCBrunettaDMVilarFC. Hematological abnormalities in HIV-infected patients. Int J Infect Dis2011; 15: e808–811.
23.
PriceJCSeabergECBadriS. HIV monoinfection is associated with increased aspartate aminotransferase-to-platelet ratio index, a surrogate marker for hepatic fibrosis. J Infect Dis2012; 205: 1005–1013.
24.
Carvalho-FilhoRJSchiavonLLNarciso-SchiavonJL. Optimized cutoffs improve performance of the aspartate aminotransferase to platelet ratio index for predicting significant liver fibrosis in human immunodeficiency virus/hepatitis C virus co-infection. Liver Int2008; 28: 486–493.
25.
DallaPiazzaMAmorosaVKLocalioR. Prevalence and risk factors for significant liver fibrosis among HIV-monoinfected patients. BMC Infect Dis2010; 10: 116–116.
26.
LazoMSelvinEClarkJM. Brief communication: clinical implications of short-term variability in liver function test results. Ann Intern Med2008; 148: 348–352.
27.
LanjewarDNRaoRJKulkarniSB. Hepatic pathology in AIDS: a pathological study from Mumbai, India. HIV Med2004; 5: 253–257.
28.
SonderupMWWainwrightHHallP. A clinicopathological cohort study of liver pathology in 301 patients with human immunodeficiency virus/acquired immune deficiency syndrome. Hepatology2015; 61: 1721–1729.
29.
SoodACastrejónMSaabS. Human immunodeficiency virus and nodular regenerative hyperplasia of liver: A systematic review. World J Hepatol2014; 6: 55–63.
30.
ScourfieldAWatersLHolmesP. Non-cirrhotic portal hypertension in HIV-infected individuals. Int J STD AIDS2011; 22: 324–328.
31.
HartlebMGutkowskiKMilkiewiczP. Nodular regenerative hyperplasia: evolving concepts on underdiagnosed cause of portal hypertension. World J Gastroenterol2011; 17: 1400–1409.
32.
ShimamatsuKWanlessIR. Role of ischemia in causing apoptosis, atrophy, and nodular hyperplasia in human liver. Hepatology1997; 26: 343–350.
33.
MuluWGideyBChernetA. Hepatotoxicity and associated risk factors in HIV-infected patients receiving antiretroviral therapy at Felege Hiwot Referral Hospital, Bahirdar, Ethiopia. Ethiop J Health Sci2013; 23: 217–226.
34.
SmithCSabinCALundgrenJD. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS2010; 24: 1537–1548.
